Treating PCOS With Semaglutide vs Active Lifestyle Intervention

Last updated: January 25, 2024
Sponsor: University of Colorado, Denver
Overall Status: Active - Not Recruiting

Phase

2/3

Condition

N/A

Treatment

Weight loss diet

Semaglutide 3mg and 7mg [Rybelsus]

Clinical Study ID

NCT03919929
19-0636
1R01DK120612-01A1
  • Ages 12-21
  • Female

Study Summary

Girls with obesity and polycystic ovarian syndrome will receive either glucagon like peptide-1 receptor agonist therapy or a dietary intervention for 12 weeks to decrease the metabolic syndrome, in particular to lower hepatic fat and improve insulin sensitivity.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Sedentary- less than 2 hours of moderate (jogging, swimming etc) exercise a week.
  2. BMI equal or greater than the 90th percentile for age and gender
  3. PCOS per the most stringent NIH criteria adapted for adolescents (irregular menses >12months post-menarche and clinical or biochemical hypertestosteronemia
  4. Participants cannot be on hormonal contraception, so participants should remainabstinent or use reliable non-hormonal contraception (e.g. copper IUD) for the entirestudy period. For participants who receive semaglutide, they should avoid pregnancyfor at least 2 months after stopping medication to avoid fetal exposure to themedication.

Exclusion

Exclusion Criteria:

  1. Diagnosed with or have a family history of medullary thyroid carcinoma (MTC) orMultiple Endocrine Neoplasia syndrome type 2 (MEN 2). Family history of medullarythyroid cancer or thyroid nodule palpated by endocrinologist at screening.
  2. Use of medications known to affect insulin sensitivity: metformin (cannot have beenused in the 3 months prior to screening), oral glucocorticoids within 10 days,atypical antipsychotics, immunosuppressant agents, HIV medications, hormonalcontraception (cannot have been used in the 6 months prior to screening). Dermal patchor vaginal ring contraception methods.Weight loss medications or stimulants. Use ofother products containing other GLP-1 agonists.
  3. Currently pregnant or breastfeeding women. Development of pregnancy during the studyperiod will necessitate withdrawal from the study.
  4. Severe illness requiring hospitalization within 60 days.
  5. Diabetes, defined as Hemoglobin A1C > 6.4%
  6. BMI percentile less than the 90th percentile for age and sex. Weight >325 lbs. or <84lbs.
  7. Anemia, defined as Hemoglobin < 11 mg/dL
  8. Diagnosed major psychiatric or developmental disorder limiting informed consent.
  9. Implanted metal devices that are not compatible with MRI
  10. Use of blood pressure medications.
  11. Known liver disease other than NAFLD or AST or ALT >100 IU/L.
  12. Personal history of pancreatitis
  13. Known renal disease of any severity or an eGFR at screening of <45ml/min/1.73m2
  14. History of severe GI disease (e.g. gastroparesis)
  15. History of gallstones
  16. Untreated thyroid disease
  17. History of hypersensitivity to semaglutide
  18. Other causes of hyperandrogenism (example: tumor, CAH) or amenorrhea (untreatedthyroid disease, tumor, primary ovarian failure, prolactinoma).
  19. Active symptoms or undergoing treatment for anorexia nervosa or binging/purgingdisorder

Study Design

Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Weight loss diet
Phase: 2/3
Study Start date:
May 03, 2019
Estimated Completion Date:
July 31, 2024

Study Description

In obese girls with polycystic ovarian syndrome, testosterone and obesity combine to create unique pathology to increase metabolic disease including fatty liver and insulin resistance, which may be mediated by altered glucagon like peptide-1 activity. The investigators will treat girls with obesity and polycystic ovarian syndrome for 4 months with a glucagon like peptide-1 receptor agonist compared to dietary intervention to primarily lower hepatic fat and secondarily improve whole body and adipose insulin sensitivity. Mechanisms of hepatic metabolism, including rates of de novo lipogenesis and relative mitochondrial flux will also be assessed.

Connect with a study center

  • University of Colorado Anshutz Medical Campus/Children's Hospital Colorado

    Aurora, Colorado 80045
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.